TABLE 2.

Impact of siRNA targeting COX-2 or PPARγ on celecoxib-elicited cytotoxic actions on A549, H460, and H358 cells

	Viability (% control)
	A549	H460	H358
Vehicle	100 ± 3	100 ± 9	100 ± 4
Celecoxib	13*** ± 3	29*** ± 2	23*** ± 3
Celecoxib + COX-2 silencing	102### ± 5	112### ± 6	89### ± 5
COX-2 silencing	123 ± 4	102 ± 8	100 ± 2
Celecoxib + nonsilencing	24 ± 6	22 ± 2	18 ± 3
Nonsilencing	108 ± 6	102 ± 8	110 ± 4
Vehicle	100 ± 6	100 ± 5	100 ± 10
Celecoxib	32*** ± 2	23*** ± 2	25*** ± 1
Celecoxib + PPARγ silencing	74#### ± 7	60### ± 4	65### ± 5
PPARγ silencing	95 ± 9	107 ± 3	98 ± 3
Celecoxib + nonsilencing	40 ± 9	13 ± 1	14 ± 2
Nonsilencing	91 ± 3	110 ± 3	102 ± 6

Cells were incubated with celecoxib (30 µM in A549 and H460; 50 µM in H358) or vehicle for 48 h. Percent control represents comparison with vehicle-treated cells (100%) in the absence of test substance. Values are means ± SEM of n = 6 experiments. ***P < 0.001 for celecoxib versus vehicle; ^##P < 0.01; ^###P < 0.001 for comparisons with celecoxib; one-way ANOVA plus Bonferroni test.